Cellectar Biosciences - 13 Year Stock Price History | CLRB
Historical daily share price chart and data for Cellectar Biosciences since 2005 adjusted for splits and dividends. Open, high, low, close (OHLC) data as well as percentage changes for multiple date ranges. Display 20, 50 and 200 day moving averages and export charts as images to use in articles and blogs. The latest closing price for Cellectar Biosciences as of October 19, 2018 is 2.69.
| Cellectar Biosciences Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2018 | 8.2309 | 13.7000 | 13.7000 | 2.1900 | 2.6900 | -80.36% |
| 2017 | 17.2692 | 12.8000 | 26.6000 | 11.2000 | 13.7000 | 12.30% |
| 2016 | 31.0365 | 73.2000 | 76.1500 | 10.5000 | 12.2000 | -83.40% |
| 2015 | 250.6595 | 306.0100 | 355.0000 | 68.5000 | 73.5000 | -76.21% |
| 2014 | 552.5469 | 760.0000 | 840.0000 | 198.9500 | 309.0000 | -58.24% |
| 2013 | 910.9524 | 1480.0000 | 1580.0000 | 600.0000 | 740.0000 | -50.00% |
| 2012 | 1921.5200 | 900.0000 | 4000.0000 | 860.0000 | 1480.0000 | 68.18% |
| 2011 | 4315.7937 | 12240.0000 | 15300.0000 | 740.0000 | 880.0000 | -90.41% |
| 2010 | 113632.8571 | 908820.0000 | 908820.0000 | 6120.0000 | 9180.0000 | -98.82% |
| 2009 | 215997.1429 | 143820.0000 | 777240.0000 | 104040.0000 | 777240.0000 | 440.43% |
| 2008 | 158587.8261 | 186660.0000 | 244800.0000 | 67320.0000 | 143820.0000 | -21.67% |
| 2007 | 260855.8566 | 275400.0000 | 416160.0000 | 131580.0000 | 183600.0000 | -31.82% |
| 2006 | 374575.6972 | 581400.0000 | 691560.0000 | 192780.0000 | 269280.0000 | -56.44% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.010B | $0.000B |
| Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in Madison, Wisconsin. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $126.867B | 19.45 |
| Abbott Laboratories (ABT) | United States | $118.574B | 24.05 |
| Stryker (SYK) | United States | $63.182B | 24.41 |
| Boston Scientific (BSX) | United States | $50.532B | 26.29 |
| Baxter (BAX) | United States | $37.110B | 25.26 |
| Zimmer Biomet Holdings (ZBH) | United States | $25.314B | 16.26 |
| ResMed (RMD) | United States | $14.694B | 29.17 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.608B | 0.00 |
| Canopy Growth (CGC) | Canada | $10.780B | 0.00 |
| Perrigo (PRGO) | Ireland | $9.837B | 13.96 |
| Bio-Rad Laboratories (BIO) | United States | $8.382B | 53.82 |
| Hill-Rom Holdings (HRC) | United States | $5.797B | 19.66 |
| Haemonetics (HAE) | United States | $5.495B | 50.15 |
| ICU Medical (ICUI) | United States | $5.418B | 36.71 |
| Insulet (PODD) | United States | $5.203B | 0.00 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.301B | 0.00 |
| Hutchison China MediTech (HCM) | China | $4.012B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.879B | 0.00 |
| Neogen (NEOG) | United States | $3.281B | 49.69 |
| NuVasive (NUVA) | United States | $3.191B | 30.27 |
| National Vision Holdings (EYE) | United States | $3.137B | 69.28 |
| Quidel (QDEL) | United States | $2.525B | 51.73 |
| NxStage Medical (NXTM) | United States | $1.815B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.784B | 25.40 |
| Cardiovascular Systems (CSII) | United States | $1.263B | 727.80 |
| AtriCure (ATRC) | United States | $1.071B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.985B | 16.09 |
| Owens & Minor (OMI) | United States | $0.934B | 9.99 |
| OraSure Technologies (OSUR) | United States | $0.904B | 59.08 |
| Cerus (CERS) | United States | $0.887B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.874B | 25.81 |
| PetIQ (PETQ) | United States | $0.862B | 28.18 |
| Surmodics (SRDX) | United States | $0.842B | 101.77 |
| MacroGenics (MGNX) | United States | $0.792B | 0.00 |
| Omeros (OMER) | United States | $0.770B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.662B | 0.00 |
| Meridian Bioscience (VIVO) | United States | $0.660B | 22.57 |
| LeMaitre Vascular (LMAT) | United States | $0.542B | 26.97 |
| Lantheus Holdings (LNTH) | United States | $0.517B | 16.07 |
| NanoString Technologies (NSTG) | United States | $0.452B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.445B | 0.00 |
| Quanterix (QTRX) | United States | $0.398B | 0.00 |
| Evolus (EOLS) | United States | $0.354B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.325B | 20.90 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.323B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.321B | 0.00 |
| Surface Oncology (SURF) | United States | $0.220B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.218B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.204B | 0.00 |
| Chimerix (CMRX) | United States | $0.173B | 0.00 |
| Fonar (FONR) | United States | $0.149B | 7.32 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.144B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.137B | 0.00 |
| United-Guardian (UG) | United States | $0.080B | 17.61 |
| Female Health (VERU) | United States | $0.075B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | Israel | $0.074B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.071B | 21.31 |
| Imprimis Pharmaceuticals (IMMY) | United States | $0.070B | 0.00 |
| Neurotrope (NTRP) | United States | $0.057B | 0.00 |
| CAS Medical Systems (CASM) | United States | $0.055B | 0.00 |
| ImmuCell (ICCC) | United States | $0.045B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.034B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.031B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.027B | 0.00 |
| Senestech (SNES) | United States | $0.020B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.019B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
